# US 2025/0144232 A1 · Programmable lipid nanoparticle delivery via corona protein engineering

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144232 A1
- Document ID: US20250144232A1
- Status: Published application
- Kind: A1
- Application number: 18/902,341
- Filed: 2024-09-30
- Published: 2025-05-08
- Earliest claimed: 2023-09-28
- Assignees: Massachusetts Institute of Technology; The Brigham and Women's Hospital, Inc.; Beth Israel Deaconess Medical Center, Inc.
- Applicants: Massachusetts Institute of Technology; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center
- Inventors: Omar Abudayyeh; Jonathan Gootenberg; Cian Schmitt-Ulms; Alisan Kayabolen
- Web page: https://patentgrep.com/patent/US20250144232A1

## CPC

- A61K 48/0033: {the non-active part being non-polymeric}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- C07K 14/775: Apolipopeptides
- A61K 48/0041: {the non-active part being polymeric}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are compositions comprising a lipid nanoparticle and a modified biomolecular corona. In some embodiments, the modified biomolecular corona comprises a fused cell-specific binding domain. In some embodiments, the modified biomolecular corona protein has been additionally modified such that it does not bind substantially to its natural receptor. In some embodiments, the fused cell-specific binding domain binds to a target cell.

## Claims

### Claim 1

A composition, comprising a lipid nanoparticle and a modified lipid binding protein; wherein the modified lipid binding protein comprises a fused cell-specific binding domain; the modified lipid binding protein has been additionally modified such that it does not bind substantially to its natural receptor; and the fused cell-specific binding domain binds to a target cell.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the lipid binding protein is a biomolecular corona protein.

### Claim 3 (depends on 1)

The composition of claim 1, wherein lipid binding protein is an Apolipoprotein.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the Apolipoprotein is ApoA-I, ApoA-II, ApoA-IV, ApoA-V, ApoB, ApoB-48 and ApoB-100, ApoC-I, ApoC-II, ApoC-III, ApoD, ApoE, ApoF, ApoH (Beta-2-glycoprotein I), ApoJ (Clusterin), ApoL, ApoM, ApoO (Apolipoprotein O), or Apo (a)-component of Lipoprotein (a).

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The composition of claim 1, wherein the lipid binding protein is a Fatty Acid Binding Protein (FABP).

### Claim 7 (depends on 6)

The composition of claim 6, wherein the Fatty Acid Binding Protein is L-FABP, I-FABP, or H-FABP.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the lipid binding protein is β2-GPI, Vtn5, a cellular retinol-binding protein (CRBP), a cellular retinoic acid-binding protein (CRABP), a sterol carrier protein (SCP), NPC1, NPC2, a StarD protein (like StarD1, StarD2), a phosphatidylserine-binding protein, an oxysterol-binding protein (OSBP), a Acyl-CoA-binding protein (ACBD), a PLIN protein, or perilipin.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the lipid binding protein is an engineered lipid binding protein.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the lipid binding protein has mutation in its receptor binding domain.

### Claim at position 11

11-16. (canceled)

### Claim 17 (depends on 1)

The composition of claim 1, wherein the cell-specific binding domain is fused to the lipid binding protein via a flexible linker.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The composition of claim 1, wherein the cell-specific binding domain is vitronectin, EGFR DARPin, an scFv, myomixer, an integrin-binding peptide, or (KKEEE) 3K binder (SEQ ID NO: 269).

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The composition of claim 1, wherein the lipid binding protein is further fused to a lipid-binding peptide.

### Claim at position 17

22-25. (canceled)

### Claim 26 (depends on 1)

The composition of claim 1, wherein the lipid binding protein comprises a mutation in its lipid-binding domain and/or its amino terminal fragment.

### Claim 27 (depends on 1)

The composition of claim 1, wherein the composition further comprises a serum-stabilizing tag.

### Claim 28

(canceled)

### Claim 29 (depends on 1)

The composition of claim 1, wherein the lipid nanoparticle and the modified lipid binding protein are mixed in a ratio of about 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10.

### Claim 30 (depends on 1)

The composition of claim 1, wherein the modified lipid binding protein is in the form of conditioned media (CM).

### Claim 31 (depends on 1)

The composition of claim 1, wherein the composition further comprises a nucleic acid.

### Claim at position 24

32-35. (canceled)

### Claim 36

A composition, comprising a lipid nanoparticle and a modified lipid binding protein; wherein the modified lipid binding protein comprises a conjugated cell-specific binding domain; the modified lipid binding protein has been additionally modified such that it does not bind substantially to its natural receptor; and the conjugated cell-specific binding domain binds to a target cell.

### Claim 37

(canceled)

### Claim 38

A composition, comprising a lipid nanoparticle and a modified lipid binding protein; wherein the lipid nanoparticle comprises a conjugated cell-specific binding domain; the modified lipid binding protein has been additionally modified such that it does not bind substantially to its natural receptor; and the conjugated cell-specific binding domain binds to a target cell.

### Claim at position 28

39-73. (canceled)

### Claim 74 (depends on 1)

A method of treating or preventing a disease, comprising administering to a subject in need thereof an effective amount of the composition of claim 1.

### Claim at position 30

75-77. (canceled)
